Selective Lymphopenia and Opportunistic Infections in Neuroendocrine Tumor Patients Receiving Temozolomide
Abraham B. Schwarzberg(Harvard University), Matthew H. Kulke(Brigham and Women's Hospital), Ann Michelini(Dana-Farber Cancer Institute), Elizabeth H. Stover(Dana-Farber Cancer Institute), Lindsey R. Baden(Brigham and Women's Hospital), Tanya P. Sengupta(Dana-Farber Cancer Institute), Michele Vincitore(Dana-Farber Cancer Institute)
Cited by 61
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
|New England Journal of Medicine|2020|1.4k
Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial
|Science|2022|1.2k
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (April 2020)
|Clinical Infectious Diseases|2020|1.1k